Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P-E Stoebner

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM Kandel, C Allayous, S Dalle, et al.
Annales De Dermatologie Et De Venereologie|July 16, 2024
Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithmF Poizeau, S Leducq, L Fardet, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
European Journal of Cancer (Oxford, England : 1990)|November 2, 2018
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM Kandel, C Allayous, S Dalle, et al.
Annales De Dermatologie Et De Venereologie|July 16, 2024
Treatment of moderate-to-severe psoriasis in adults: An expert consensus statement using a Delphi method to produce a decision-making algorithmF Poizeau, S Leducq, L Fardet, et al.
Annales De Dermatologie Et De Venereologie|February 7, 2024
The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concernsM Amini-Adle, J-P Arnault, F Aubin, et al.
Pageof 4